The Early Phase Clinical Trial Units (EPCTUs) support the design, development, implementation, and conduct of Phase 0 to Phase 2 clinical trials, including proof-of-concept studies in healthy, special, and disease-specific populations, carried out in an expeditious and efficient manner, aided by bioanalysis when necessary, against viral, bacterial, parasitic, and fungal pathogens and emerging and re-emerging infectious diseases. The candidate products assessed through the EPCTUs may include licensed or investigational products such as small molecules, monoclonal antibodies, i

Therapeutic Development Services - Interventional Agents program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious pathogens, including bacteria, viruses, parasites, fungi, and toxins. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.

Note: Devices are excluded.

The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical specimens.

This is one of several programs provided by NIAID's Division of Microbiology and Infectious Diseases to support infectious disease product developers.

Provides services to facilitate preclinical development of materials that are derived from biotechnology processes. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.

The GCID use, develop and improve innovative applications of genomic technologies, such as DNA and RNA sequencing and metagenomics, and provide rapid and cost-efficient production of high-quality genome sequences of microorganisms, invertebrate vectors of infectious diseases, and hosts and host microbiomes.

This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo and complex human cell-based in vitro model preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.

The BEI Resources Repository is a central repository that supplies organisms and reagents to the broad community of microbiology and infectious diseases researchers. Materials are available through an online catalog. There is no charge for research materials, but domestic investigators will be required to pay for shipping costs.

Highlights